Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19066279 | EXOSOME SYSTEMS, PRODUCTS AND METHODS | February 2025 | April 2025 | Allow | 1 | 0 | 0 | No | No |
| 18412403 | EXOSOMES FOR TARGET SPECIFIC DELIVERY AND METHODS FOR PREPARING AND DELIVERING THE SAME | January 2024 | August 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18264181 | MODULATION OF MAMMALIAN CELL LINEAGE BY SYNTHETIC IMMODULINS | August 2023 | May 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18353182 | COMPOSITION FOR CULTURING NK CELLS AND METHOD FOR CULTURING NK CELLS USING SAME | July 2023 | January 2024 | Allow | 6 | 1 | 0 | No | No |
| 18221658 | METHODS AND MATERIALS FOR EXPANDING ANTIGEN-SPECIFIC T CELLS IN CULTURE | July 2023 | May 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18331353 | ENHANCED MSC PREPARATIONS | June 2023 | May 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18196779 | HIGHLY ACTIVE NK CELL AND USE THEREOF | May 2023 | February 2025 | Allow | 21 | 1 | 0 | No | No |
| 18132713 | CELL THERAPY COMPOSITIONS AND METHODS OF USE THEREOF | April 2023 | April 2025 | Allow | 24 | 1 | 0 | No | No |
| 18297491 | TGFBETA SIGNAL CONVERTOR | April 2023 | March 2025 | Allow | 23 | 1 | 0 | No | No |
| 18296065 | REGULATORY MACROPHAGES FOR TREATING ANGIOPATHIES | April 2023 | March 2025 | Allow | 23 | 1 | 0 | Yes | No |
| 18189826 | CANCER-KILLING CELLS | March 2023 | March 2025 | Allow | 24 | 2 | 0 | No | No |
| 18118941 | METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS | March 2023 | December 2024 | Allow | 21 | 1 | 0 | No | No |
| 18153900 | EXPANSION OF GAMMA DELTA T CELLS, COMPOSITIONS, AND METHODS OF USE THEREOF | January 2023 | July 2025 | Allow | 30 | 2 | 0 | No | No |
| 18050915 | HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODY | October 2022 | May 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 17975187 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | October 2022 | August 2023 | Allow | 10 | 0 | 0 | No | No |
| 18050005 | PREPARATION OF THERAPEUTIC EXOSOMES USING MEMBRANE PROTEINS | October 2022 | November 2024 | Allow | 25 | 1 | 0 | No | No |
| 18049999 | EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY | October 2022 | December 2024 | Allow | 25 | 1 | 0 | No | No |
| 18045868 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | October 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17938549 | DICKKOPF2 (DKK2) INHIBITION SUPPRESSES TUMOR FORMATION | October 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17900994 | COMPOSITION OF EXTRACELLULAR VESICLES (EVS) AND MEDICAL USES THEREOF | September 2022 | September 2024 | Allow | 25 | 1 | 0 | No | No |
| 17898540 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | August 2022 | October 2024 | Allow | 26 | 1 | 0 | No | No |
| 17867321 | ENGRAFTMENT OF STEM CELLS WITH A COMBINATION OF AN AGENT THAT TARGETS STEM CELLS AND MODULATION OF IMMUNOREGULATORY SIGNALING | July 2022 | November 2024 | Allow | 27 | 1 | 0 | No | No |
| 17854239 | Immunoconjugates Targeting HER2 | June 2022 | January 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17836998 | Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the Same | June 2022 | October 2024 | Allow | 28 | 1 | 0 | No | No |
| 17825652 | RENAL CELL POPULATIONS AND USES THEREOF | May 2022 | February 2025 | Allow | 32 | 1 | 1 | No | No |
| 17752481 | TUMOR-INFILTRATING LYMPHOCYTES FOR ADOPTIVE CELL THERAPY | May 2022 | November 2024 | Allow | 30 | 1 | 0 | No | No |
| 17660382 | Antigen Binding Molecules That Bind LIGHT | April 2022 | October 2024 | Allow | 30 | 1 | 0 | No | No |
| 17719825 | Inhibition of Cytokine-Induced SH2 Protein in NK Cells | April 2022 | September 2022 | Allow | 5 | 1 | 0 | No | No |
| 17768061 | NEW REGULATORY MACROPHAGES AND USES THEREOF | April 2022 | April 2025 | Allow | 36 | 1 | 0 | No | No |
| 17715558 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELL (CAR-DC) FOR TREATMENT OF CANCER | April 2022 | September 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17713766 | COMPOSITIONS AND METHODS FOR PROMOTING PATENCY OF VASCULAR GRAFTS | April 2022 | September 2024 | Allow | 29 | 1 | 0 | Yes | No |
| 17702734 | HETERODIMERIC PROTEINS | March 2022 | June 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17696779 | METHODS OF CELL THERAPIES | March 2022 | June 2023 | Allow | 15 | 2 | 0 | No | No |
| 17654778 | METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS AND VASCULOGENESIS | March 2022 | August 2024 | Allow | 29 | 1 | 0 | No | No |
| 17688435 | METHODS OF PRODUCING MODIFIED NATURAL KILLER CELLS AND METHODS OF USE | March 2022 | June 2025 | Allow | 40 | 1 | 0 | No | No |
| 17651673 | UTILIZING THE INNATE IMMUNE SYSTEM TO DELIVER THERAPEUTIC AGENTS | February 2022 | September 2024 | Allow | 31 | 1 | 0 | No | No |
| 17667934 | METHODS, COMPOSITIONS, AND KITS FOR PRODUCING BEIGE ADIPOCYTES AND TREATING METABOLIC DISORDERS | February 2022 | January 2025 | Allow | 36 | 2 | 0 | No | No |
| 17544636 | VACCINES FOR USE IN TREATING VARIOUS DISEASES AND DISORDERS | December 2021 | October 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17538719 | COMPOSITIONS AND METHODS FOR DIFFERENTIATING STEM CELLS INTO NK CELLS | November 2021 | May 2022 | Allow | 6 | 1 | 0 | Yes | No |
| 17511322 | ACTIVATED STEM CELLS AND SYSTEMIC TREATMENT METHODS FOR INFECTED WOUNDS | October 2021 | January 2025 | Allow | 39 | 2 | 0 | No | No |
| 17500832 | NERVE REGENERATION | October 2021 | September 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17499043 | C1q AND HMGB1 FUSION PROTEINS AND USES THEREOF | October 2021 | March 2024 | Allow | 29 | 0 | 0 | No | No |
| 17483193 | NATURAL KILLER CELL CONTAINING EXOGENOUS MITOCHONDRIUM AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | September 2021 | July 2024 | Allow | 34 | 1 | 0 | No | No |
| 17465284 | Immunoconjugates Targeting HER2 | September 2021 | April 2022 | Allow | 7 | 1 | 0 | No | No |
| 17460867 | Autoimmune Disease Treatment With Chemokine-Loaded Alginate Microparticles | August 2021 | August 2024 | Allow | 36 | 1 | 0 | No | No |
| 17406504 | ANTI-DLL3 ANTIBODY | August 2021 | August 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17395103 | DEPLETING TUMOR-SPECIFIC TREGS | August 2021 | October 2024 | Allow | 38 | 2 | 0 | No | No |
| 17393466 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | August 2021 | February 2022 | Allow | 6 | 1 | 0 | No | No |
| 17384207 | IL2 AND TNF MUTANT IMMUNOCONJUGATES | July 2021 | August 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17380404 | SITE DIRECTED MUTAGENESIS OF TREM-1 ANTIBODIES FOR DECREASING VISCOSITY | July 2021 | June 2024 | Allow | 35 | 1 | 0 | No | No |
| 17379128 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | July 2021 | January 2022 | Allow | 6 | 1 | 0 | No | No |
| 17351452 | WNT/SFRP COMPLEXES, WNT-CONTAINING COMPOSITIONS, WNT-EXPRESSING CELLS, AND METHODS OF MAKING, PURIFYING, AND USING SAME | June 2021 | July 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17314438 | COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE | May 2021 | July 2024 | Abandon | 38 | 1 | 0 | No | No |
| 17291808 | USE OF LACTOFERRIN FOR GENERATING MYELOID-DERIVED SUPPRESSOR CELLS | May 2021 | January 2025 | Allow | 44 | 2 | 0 | No | No |
| 17307754 | METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS | May 2021 | August 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17307658 | METHODS FOR THE PRODUCTION OF TCR GAMMA DELTA + T CELLS | May 2021 | August 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17224966 | NK CELLS EXHIBITING AN ADAPTIVE PHENOTYPE AND METHODS FOR PREPARING AND FOR USING | April 2021 | March 2024 | Allow | 36 | 1 | 0 | No | No |
| 17224047 | METHODS FOR THE PRODUCTION OF THERAPEUTIC, DIAGNOSTIC, OR RESEARCH ANTIBODIES | April 2021 | March 2024 | Allow | 36 | 1 | 0 | No | No |
| 17222761 | MONOCLONAL ANTIBODY COMPOSITION FOR TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA | April 2021 | April 2025 | Allow | 48 | 2 | 0 | No | No |
| 17211631 | MONOCLONAL ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR (TFPI) | March 2021 | January 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17211625 | Cell Expression System | March 2021 | February 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17209554 | METHODS AND COMPOSITIONS FOR TREATING DISEASE-RELATED CACHEXIA | March 2021 | December 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17195518 | IL-18 BINDING PROTEIN (IL-18BP) AND ANTIBODIES IN INFLAMMATORY DISEASES | March 2021 | October 2023 | Allow | 32 | 1 | 0 | No | No |
| 17274021 | CHIMERIC RECEPTOR POLYPEPTIDES IN COMBINATION WITH TRANS METABOLISM MOLECULES MODULATING INTRACELLULAR LACTATE CONCENTRATIONS AND THERAPEUTIC USES THEREOF | March 2021 | September 2024 | Abandon | 42 | 0 | 1 | No | No |
| 17185801 | PROCESSES FOR MAKING AND USING A MESENCHYMAL STEM CELL DERIVED SECRETOME | February 2021 | August 2021 | Allow | 6 | 1 | 0 | No | No |
| 17269027 | MIC THERAPY FOR SPECIFIC IMMUNOSUPPRESSION IN TRANSPLANTATION | February 2021 | September 2022 | Allow | 19 | 2 | 0 | Yes | No |
| 17263835 | CONDITIONED MEDIUM AND EXTRACELLULAR MATRIX COMPOSITIONS AND USES THEREOF | January 2021 | March 2025 | Allow | 50 | 1 | 1 | No | No |
| 17151085 | GENERATING CIK NKT CELLS FROM CORD BLOOD | January 2021 | February 2022 | Allow | 13 | 2 | 1 | No | No |
| 17260544 | GENERATING CIK NKT CELLS FROM CORD BLOOD | January 2021 | November 2024 | Abandon | 46 | 0 | 1 | No | No |
| 17133448 | METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES | December 2020 | December 2023 | Allow | 36 | 1 | 0 | No | No |
| 17247515 | METHOD FOR MODULATING APPETITE | December 2020 | September 2024 | Abandon | 45 | 2 | 0 | No | No |
| 17115896 | INHIBITION OF CYTOKINE-INDUCED SH2 PROTEIN IN NK CELLS | December 2020 | July 2021 | Allow | 7 | 1 | 0 | No | No |
| 17057646 | ANTI-ROR1 ANTIBODY AND USE THEREOF | November 2020 | June 2024 | Allow | 43 | 1 | 0 | No | No |
| 16953459 | THERAPEUTIC AND DIAGNOSTIC TARGET FOR CANCER COMPRISING DLL3 BINDING REAGENTS | November 2020 | November 2023 | Abandon | 36 | 0 | 1 | No | No |
| 17055303 | ANTI-MUC1 ANTIBODY | November 2020 | November 2024 | Allow | 48 | 2 | 0 | No | No |
| 17093387 | TREATMENT OF ASTHMA WITH ANTI-TSLP ANTIBODY | November 2020 | November 2024 | Abandon | 48 | 2 | 0 | No | No |
| 17089999 | HUMANIZED MONOCLONAL ADVANCED GLYCATION END-PRODUCT ANTIBODY | November 2020 | November 2021 | Allow | 12 | 0 | 0 | No | No |
| 17050299 | Compositions and Methods for Retrieving Tumor-related Antibodies and Antigens | October 2020 | March 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 17050161 | ANTIBODY AGAINST TIM-3 AND APPLICATION THEREOF | October 2020 | September 2023 | Allow | 34 | 0 | 0 | No | No |
| 17075721 | THERAPEUTIC POOLED BLOOD APOPTOTIC CELL PREPARATIONS AND USES THEREOF | October 2020 | September 2023 | Allow | 35 | 1 | 0 | No | No |
| 17072703 | ANTI-TUMOR COMPOSITIONS AND USES THEREOF | October 2020 | March 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17063204 | METHODS FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO IMMUNE CELLS | October 2020 | June 2024 | Allow | 44 | 2 | 0 | No | No |
| 17045130 | ANTI-CHEMOKIN LIKE RECEPTOR 1 ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | October 2020 | February 2024 | Allow | 40 | 1 | 0 | No | No |
| 17039671 | COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE | September 2020 | September 2023 | Allow | 35 | 1 | 0 | No | No |
| 17028648 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | September 2020 | November 2023 | Allow | 38 | 1 | 0 | No | No |
| 17010178 | FUSION IMMUNOMODULATORY PROTEINS AND METHODS FOR MAKING SAME | September 2020 | May 2024 | Allow | 45 | 2 | 0 | No | No |
| 17009558 | METHOD OF PRODUCING NATURAL KILLER CELLS AND COMPOSITION FOR TREATING CANCER | September 2020 | October 2023 | Allow | 37 | 1 | 0 | No | No |
| 17007415 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | August 2020 | August 2023 | Allow | 36 | 1 | 0 | No | No |
| 16976285 | METHODS AND COMPOSITIONS RELATING TO EPOXIDE HYDROLASE GENES | August 2020 | February 2024 | Allow | 42 | 1 | 0 | No | No |
| 16971144 | CD153 AND/OR CD30 IN INFECTION | August 2020 | June 2024 | Abandon | 46 | 1 | 1 | No | No |
| 16063423 | DKK2 CYSTEINE RICH DOMAIN 2 CONTAINING PROTEINS AND USES THEREOF | August 2020 | February 2024 | Abandon | 60 | 1 | 0 | No | No |
| 16970473 | EXPANSION OF NK AND DC CELLS IN VIVO MEDIATING IMMUNE RESPONSE | August 2020 | January 2024 | Allow | 41 | 2 | 0 | No | No |
| 16986755 | METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS | August 2020 | August 2023 | Allow | 36 | 1 | 0 | No | No |
| 16965816 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | July 2020 | November 2023 | Allow | 40 | 1 | 0 | No | No |
| 16961088 | T CELL RECEPTORS FOR IMMUNOTHERAPY | July 2020 | October 2023 | Allow | 40 | 1 | 0 | Yes | No |
| 16921351 | EXOSOMES FOR IMMUNO-ONCOLOGY AND ANTI-INFLAMMATORY THERAPY | July 2020 | February 2024 | Allow | 44 | 2 | 0 | No | No |
| 16917156 | SOMATIC STEM CELLS | June 2020 | October 2023 | Abandon | 40 | 1 | 0 | No | No |
| 16772967 | T Regulatory (Treg) Cell Transplantation in Osteogenesis Imperfecta (OI) | June 2020 | January 2024 | Allow | 43 | 1 | 0 | No | No |
| 16887029 | Compositions containing protein loaded exosome and methods for preparing and delivering the same | May 2020 | August 2023 | Allow | 38 | 1 | 0 | No | No |
| 16887971 | FIBROBLAST THERAPY FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | May 2020 | May 2024 | Allow | 47 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GAMETT, DANIEL C.
With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 9.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner GAMETT, DANIEL C works in Art Unit 1647 and has examined 1,090 patent applications in our dataset. With an allowance rate of 64.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 31 months.
Examiner GAMETT, DANIEL C's allowance rate of 64.1% places them in the 17% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GAMETT, DANIEL C receive 1.72 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GAMETT, DANIEL C is 31 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +32.2% benefit to allowance rate for applications examined by GAMETT, DANIEL C. This interview benefit is in the 83% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.9% of applications are subsequently allowed. This success rate is in the 40% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 58.7% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 82.9% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 79.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.2% of allowed cases (in the 94% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 1.4% of allowed cases (in the 61% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.